Treatment with Endeavor Biomedicines’ experimental oral therapy ENV-101 (taladegib) improved lung function in people with IPF ...

An announcement from Vicore Pharma Holding AB ( ($SE:VICO) ) is now available. Vicore Pharma Holding AB announced a directed share issue to raise ...

Each year, the European Lung Foundation (ELF) recognises outstanding research that advances patient-centred care and promotes ...

Insilico Medicine to showcase generative AI platform and introduce their latest AI-driven Pulmonary Fibrosis clinical research at PFF Summit 2025 in Chicago, IL ...

AI transforms healthcare by enhancing disease detection, patient care and hospital efficiency but requires careful implementation to ensure equity and effectiveness. Managed Healthcare Executive ...

Patent covers brilaroxazine use for treating Pulmonary Fibrosis-Similar patents have also been granted in key markets around the world ...

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with ...

Angiotensin-converting enzyme (ACE) inhibitor therapy may reduce all-cause mortality in idiopathic pulmonary fibrosis (IPF) but not in COPD.

Learn more about whether Arrowhead Pharmaceuticals, Inc. or Viridian Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Patients with refractory chronic cough who received twice-daily Haduvio for 21 days had decreases in cough frequency and ...

The investigators also reported that LTI-03 helped preserve alveolar epithelial type II (AT2) progenitor cells, which are essential for lung repair and regeneration. Current IPF therapies primarily ...

A Phase 2 trial testing experimental therapy CAL101 in people with IPF is recruiting participants. CAL101 has been granted ...